Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2026)

Recursion Pharmaceuticals' Operating Leases history runs 5 years deep, the most recent figure standing at $42.8 million for Q1 2026.

• Quarterly Operating Leases fell 23.53% year-over-year to $42.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 23.53% YoY) and the FY2025 annual result came in at $46.6 million, down 30.64% from the prior year.
• Operating Leases was $42.8 million for Q1 2026 at Recursion Pharmaceuticals, down from $46.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.8 million in Q2 2024 and bottomed at $42.8 million in Q1 2026.
• A 5-year average of $52.5 million and a median of $50.0 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases soared 73.82% — and 2025, when it plunged 39.85%.
• Recursion Pharmaceuticals' Operating Leases stood at $44.4 million in 2022, then decreased by 2.26% to $43.4 million in 2023, then surged by 54.9% to $67.2 million in 2024, then tumbled by 30.64% to $46.6 million in 2025, then slipped by 8.16% to $42.8 million in 2026.
• Business Quant data shows RXRX's Operating Leases at $42.8 million in Q1 2026, $46.6 million in Q4 2025, and $50.0 million in Q3 2025.